Abstract: OBJECTIVE To explore the effect of entecavir on treatment of hepatitis B. METHODS A total of 80 patients with CHB who were treated from Jun 2016 to Jun 2017 were enrolled in the study, and the patients were treated with oral administration of entecavir dispersible tablets for 48 weeks. The levels of serum HBsAg and HBV DNA were quantitatively detected before the treatment and after the treatment for 12, 24, 36 and 48 weeks. RESULTS The effective rate of treatment of the 80 patients was 85.00%. The levels of serum HBsAg and HBV DNA of the effective group were significantly lower than those of the ineffective group after the treatment for 12,24, 36 and 48 weeks (all P<0.05). The serum HBsAg level of the effective group began to decline after the treatment for 12 weeks (P<0.05), while the serum HBsAg level of the ineffective group began to decline after the treatment for 36 weeks (P<0.05). The serum HBV DNA level of both groups began to decline after the treatment for 12 weeks (P<0.05). Pearson correlation analysis showed that the serum HBsAg level was positively correlated with the HBV-DNA level after the treatment (P<0.05). The area under ROC curve indicated that the serum HBsAg level was 3.87 lg IU/ml on week 24 of treatment, the sensitivity was 83.19% for prediction of effect of antiviral therapy, and the specificity was 77.20%. CONCLUSION The serum HBsAg level is not associated with the effect of antiviral treatment with entecavir dispersible tablets before the treatment, wile the serum HBsAg level is closely associated with the curative effect during the treatment, and the patients whose serum HBsAg level is remarkably reduced on Week 24 of treatment have better later treatment effect.